Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
暂无分享,去创建一个
Hongtao Song | Ying Liu | Qingwei Meng | Li Cai | Xiaoqun Dong | Y. Liu | Yan-bin Zhao | L. Cai | Hailing Lu | Xiaoqun Dong | Qing-wei Meng | Hailing Lu | Hui Pang | Yanbin Zhao | Na Liu | Fei Lan | Suhong Yan | Hongtao Song | H. Pang | Fei-Fei Lan | Na Liu | S. Yan | Qingwei Meng
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] S. Schwartz,et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.
[3] Boecker,et al. Immunophenotypic and prognostic analysis of E‐cadherin and β‐catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44 , 1999, Histopathology.
[4] Mansoor M Ahmed,et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.
[5] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[6] V. Bramwell,et al. Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[7] F. Walsh,et al. Epithelial (E‐) and placentae (P‐) cadherin cell adhesion molecule expression in breast carcinoma , 1993, The Journal of pathology.
[8] Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. , 1999 .
[9] S. Pinder,et al. An immunohistochemical examination of the expression of E‐cadherin, α‐ and β/γ‐catenins, and α2‐ and β1‐integrins in invasive breast cancer , 1999, The Journal of pathology.
[10] E. Thompson,et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[11] Dino Amadori,et al. The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.
[12] S. Stock,et al. Regulation of Breast Cancer-induced Bone Lesions by β-Catenin Protein Signaling* , 2011, The Journal of Biological Chemistry.
[13] Christian Wittekind,et al. Cancer Invasion and Metastasis , 2005, Oncology.
[14] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[15] W. Jiang,et al. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. , 2008, Anticancer research.
[16] Mi-Sook Lee,et al. Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer , 2002 .
[17] Lan Chao,et al. Increased expression of osteopontin in patients with triple‐negative breast cancer , 2008, European journal of clinical investigation.
[18] M. Takeichi,et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.
[19] G. Weber,et al. Osteopontin‐c is a selective marker of breast cancer , 2008, International journal of cancer.
[20] A. Chambers,et al. Activation of MMP‐2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent , 1998, International journal of cancer.
[21] A. Ribeiro-Silva,et al. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. , 2008, The International journal of biological markers.
[22] P. Kuo,et al. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer , 2009, BMC Research Notes.
[23] M. Rubin,et al. E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.
[24] D. Miles,et al. Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast , 2001, The Journal of pathology.
[25] F. O'Malley,et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] David L Rimm,et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.
[27] J. Jónasson,et al. Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. , 1999, European journal of cancer.
[28] F. Akiyama,et al. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer , 2014, Breast Cancer.
[29] Barbara L. Smith,et al. The effect of tumor size and lymph node status on breast carcinoma lethality , 2003, Cancer.
[30] M. C. Ling,et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.
[31] E. Rollo,et al. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme , 1995, Clinical & Experimental Metastasis.
[32] R. Samant,et al. Osteopontin: an effector and an effect of tumor metastasis. , 2010, Current molecular medicine.
[33] Xinjie Lin,et al. Osteopontin Deficiency in Rat Vascular Smooth Muscle Cells is Associated with an Inability to Adhere to Collagen and Increased Apoptosis , 2000, Laboratory Investigation.
[34] A. Leong,et al. The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment , 2011, Pathobiology.
[35] G. Weber,et al. An osteopontin splice variant induces anchorage independence in human breast cancer cells , 2006, Oncogene.
[36] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[37] Kevin Hughes,et al. Predicting the survival of patients with breast carcinoma using tumor size , 2002, Cancer.
[38] F. O'Malley,et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. , 1997, Archives of pathology & laboratory medicine.
[39] G. Casey,et al. Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.
[40] A. Chambers,et al. Osteopontin‐induced, integrin‐dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) , 2000, Journal of cellular biochemistry.
[41] L. Cai,et al. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. , 2011, Cancer biotherapy & radiopharmaceuticals.
[42] A. Chambers,et al. Overcoming obstacles to metastasis ‐ defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells , 1994, Journal of cellular biochemistry.
[43] T. Rowlands,et al. Cadherins and catenins in breast cancer. , 2005, Current opinion in cell biology.
[44] G. Casey,et al. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1 , 2008, International journal of cancer.
[45] S. Kuo,et al. Triple negative breast carcinoma is a prognostic factor in Taiwanese women , 2009, BMC Cancer.
[46] C. Gilles,et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. , 1998, Experimental cell research.
[47] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[48] N. Duraker,et al. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes , 2005, Cancer.
[49] G. Weber,et al. Osteopontin is a marker for cancer aggressiveness and patient survival , 2010, British Journal of Cancer.
[50] D. Fennell,et al. Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer , 2011, British Journal of Cancer.
[51] G. Weber,et al. Categorical meta-analysis of Osteopontin as a clinical cancer marker. , 2011, Oncology reports.